MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, BDX made $4,714M in revenue. -$37M in net income. Net profit margin of -0.78%.

Income Overview

Revenue
$4,714M
Net Income
-$37M
Net Profit Margin
-0.78%
EPS
-$1.11
Unit: Million (M) dollars
Revenue Breakdown
    • Medical Essentials
    • Interventional
    • Connected Care
    • Bio Pharma Systems
Revenue Breakdown
    • US
    • Non Us

Income Statement
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Revenues
4,714 5,252 5,891 5,509
Cost of products sold
2,560 2,841 3,092 2,875
Selling and administrative expense
1,213 1,393 1,367 1,320
Research and development expense
249 306 323 297
Integration, restructuring and transaction expense
533 111 129 97
Other operating expense, net
-66 -50 -285 -38
Total operating costs and expenses
4,620 4,700 5,194 4,627
Operating income
93 552 698 882
Interest expense
149 153 155 152
Interest income
9 4 5 5
Other income (expense), net
86 -10 -36 -33
Income from continuing operations before income taxes
39 393 509 703
Income tax provision
76 11 16 129
Net (loss) income from continuing operations
-37 -493* -
Loss from discontinued operations, net of tax
--0* -
Net income
-382 493 574
Preferred stock dividends
--0 -
Net income applicable to common shareholders
--493 -
Basic EPS
-1.11 1.34 1.72 2
Diluted EPS
-1.11 1.34 1.708 2
Basic Average Shares
280,640,000 285,582,000 286,624,000 287,170,000
Diluted Average Shares
280,640,000 285,845,000 288,687,000 287,223,000
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
US$965M (-68.95%↓ Y/Y)Non Us$682M (-68.48%↓ Y/Y)US$933M (-69.98%↓ Y/Y)Non Us$423M (-80.45%↓ Y/Y)US$840M (-72.97%↓ Y/Y)Non Us$280M (-87.06%↓ Y/Y)Non Us$411M (-81.01%↓ Y/Y)US$178M (-94.27%↓ Y/Y)Medical Essentials$1,647M Interventional$1,357M Connected Care$1,120M Bio Pharma Systems$590M Revenues$4,714M (-10.58%↓ Y/Y)Operating income$93M (-82.97%↓ Y/Y)Other income(expense), net$86M (326.32%↑ Y/Y)Interest income$9M (80.00%↑ Y/Y)Total operating costsand expenses$4,620M (-2.22%↓ Y/Y)Net (loss) incomefrom continuing...-$37M Income from continuingoperations before income...$39M (-89.26%↓ Y/Y)Interest expense$149M (-1.32%↓ Y/Y)Cost of products sold$2,560M (-15.09%↓ Y/Y)Selling andadministrative expense$1,213M (-4.71%↓ Y/Y)Integration, restructuringand transaction...$533M (492.22%↑ Y/Y)Research and developmentexpense$249M (-17.55%↓ Y/Y)Other operatingexpense, net-$66M (-46.67%↓ Y/Y)Income tax provision$76M (38.18%↑ Y/Y)

header-bd-logo-svg

BECTON DICKINSON & CO (BDX)

header-bd-logo-svg

BECTON DICKINSON & CO (BDX)